Eli Lilly is getting more opaque as it gets bigger.
Earlier this year, the drugmaker stopped disclosing its early-stage pipeline work. Its Phase 1 projects vanished from the company’s earnings presentation and were pulled from ...
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.